Diabetes Solutions Landscape, US Phase 2, Part 1 CLEAN UP - Virta and Omada

Part
01
of one
Part
01

Diabetes Solutions Landscape, US Phase 2, Part 1 CLEAN UP - Virta and Omada

As requested, the data presented rows 12 and 13 of the attached spreadsheet have been cleaned and revised where needed, based on the outlined feedback. All the sources and answers in each cell were checked again and following rows were updated in the spreadsheet, on the basis of outlined feedback:
12L: Yes, Virta's stated mission is to slow progression of cardio-metabolic disease and related complications. Under "How we do it" section of its homepage, it is clearly mentioned that "Virta is the first clinically-proven treatment to safely and sustainably reverse type 2 diabetes".
12T: Neither approved nor endorsed by medical association.
12V: Despite extensive searching through press releases, media coverage, company publications, government websites, association websites, and other sources, no evidence was found of regulatory approval or endorsement by one of the listed medical associations.
12W: None
12X: Despite extensive searching through press releases, media coverage, company publications, and other sources, no evidence was found of any partnerships with public or private healthcare payers.
12Y: Series B
12AB: 330
12AD: After extensive searching, I could not find Virta on Google Play, therefore information on the number of downloads could not be found via this method. However, the number of iOS downloads of an app can be calculated by the following formula:
30*Number of Ratings.
Hence, the estimated number of Virta downloads can be triangulated as follows:
30 * Number of ratings=30*11=330
Since it is an app and not a medical device, the number of units sold per year is not applicable.
12AI: 11
12AJ: After extensive searching, I could not find Virta on Google Play, therefore only App store ratings are considered.
12AM: 262 adult volunteers having type 2 diabetes for 8 years were enrolled in this trial and 30% of them were prescribed insulin when enrolled. After the trial of five years, patients receiving the continuous care from Virta utilizing nutritional ketosis had significant reductions in HbA1c, weight, and medication use in comparison to 87 adult volunteers who received the usual care for type 2 diabetes in that specific period.
Under "Virta's Clinical Trial ", there are given the proven impact against stated goals. These have been used because of lack of availability of credible reviews on Virta from other sources.
13P: Yes.
13S: As of 2017, over 15,000 are currently active registered participants of Omada.
13Z: $126,500,000
13AL: Omada Health didn't participate in this study/model design and data analysis. These risk-reduction calculations are made through study model using Omada Health participants' average weight loss and demographic factors in October 2016. The actual results might be different due to reasons like gender, age, or other demographic factors.
All the information provided above has been updated and other minor errors including footnotes have been cleaned in the spreadsheet.

Sources
Sources